You are here: Industry Insights > Tocilizumab

News List

Second Biosimilar Tocilizumab Injection approved for marketing www.nmpa.com
January 18, 2023
Second Biosimilar Tocilizumab Injection approved for marketing.
Biosimilar Tocilizumab Injection approved for marketing www.nmpa.com
January 16, 2023
Biosimilar Tocilizumab Injection approved for marketing.
COVID treatment: Centre issues revised guidelines on use of drugs and therapies ExpressPharma
January 19, 2022
The revised guidelines continue to recommend Emergency Use Authorisation (EUA) or off-label use of Remdesivir in patients with moderate-to-severe disease...
Theramex, Enzene Biosciences Partner on Arthritis Treatment contractpharma
January 05, 2022
Will develop and commercialize Tocilizumab, a biosimilar for the treatment of rheumatoid arthritis.
Centre increases supply of essential drugs for COVID expresspharma
August 05, 2021
The availability of all major drugs required for the management of COVID-19 was regularly monitored through weekly surveys of retail pharmacies, said Health Minister.
Roche gives Tocilizumab worth over Rs 40 crores to MoHFW expresspharma
May 14, 2021
The supplies reached India on May 11, 2021, and will be handed over to the MohFW in the next few days.
COVID-19 treatments update: hydroxychloroquine and tocilizumab europeanpharmaceuticalreview
March 04, 2021
Find out what the WHO has to say about the use of hydroxychloroquine in COVID-19 prevention and the results of a severe COVID-19 pneumonia trial with tocilizumab.
Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients worldpharmanews
March 01, 2021
Treating critically ill COVID-19 patients with drugs typically used for rheumatoid arthritis may significantly improve survival, a landmark study has found.
NHS to roll-out tocilizumab treatment for COVID-19 pharmatimes
February 20, 2021
The UK government has announced that an arthritis med, tocilizumab, will be offered to thousands more NHS patients after the drug was found to reduce the risk of death in people with COVID-19.
Tocilizumab and sarilumab reduce COVID-19 patient mortality by 8.5 percent, data shows europeanpharmaceuticalreview
January 08, 2021
IL-6 receptor antagonists tocilizumab and sarilumab have a significant impact on COVID-19 patient mortality, a study has shown.

Previous page 1 2 3 Next page